Prevail Therapeutics Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Tyto Acquisition Corp, was filed 22 Jan 2021.
Prevail Therapeutics Inc.: what insiders have been doing
Prevail Therapeutics Inc. is a listed company. Its directors and officers file their transactions with SEC (Form 4). Nothing new has been filed by managers of Prevail Therapeutics Inc. in twelve months, the latest record being from 26 January 2021.
Since 2019, the database holds 2 purchases and no sales by insiders of the company.
Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2019FY ended December 2019 · cache
- 23,747 sharesCommon StockSEC:0001209191-21-005429:0
- 13,822,463 sharesCommon StockSEC:0001209191-21-005406:0
- 1,576,881 sharesCommon StockSEC:0001209191-21-005410:0
- 13,822,463 sharesCommon StockSEC:0001209191-21-005408:0
- 13,822,463 sharesCommon StockSEC:0001209191-21-005464:0
- 2,385,756 sharesCommon StockSEC:0001209191-21-005459:0
- 13,000 sharesCommon StockSEC:0001209191-21-005432:0
- 34,284,789 shares@ US$22.50100.0% of flowCommon StockSEC:0000899243-21-002923:0Canonical exit: 22 Apr 2021 (T+90)
- 5,256 shares@ US$0.180.0% of flowCommon StockSEC:0001209191-20-065696:0
- 120,537 shares@ US$10.2637.6% of flowCommon StockSEC:0001209191-20-065696:1
- 89,037 shares@ US$23.0262.4% of flowCommon StockSEC:0001209191-20-065696:2
- 13,000 shares@ US$0.18100.0% of flowCommon StockSEC:0001209191-20-018117:0
- 10,510,111 sharesCommon StockSEC:0001209191-19-039126:0
- 10,510,111 sharesCommon StockSEC:0001209191-19-039130:0
- 10,510,111 sharesCommon StockSEC:0001209191-19-039127:0
- 882,352 shares@ US$17.00100.0% of flowCommon StockSEC:0001209191-19-039126:1Canonical exit: 22 Sept 2019 (T+90)
- 882,352 shares@ US$17.00100.0% of flowCommon StockSEC:0001209191-19-039130:1Canonical exit: 22 Sept 2019 (T+90)
- 882,352 shares@ US$17.00100.0% of flowCommon StockSEC:0001209191-19-039127:1Canonical exit: 22 Sept 2019 (T+90)
- 23,747 sharesCommon StockSEC:0001209191-19-039015:0
19 of 19 declarations
About Prevail Therapeutics Inc.
Prevail Therapeutics Inc. is a biopharmaceutical company focused on developing gene therapies for neurodegenerative diseases. It aims to provide innovative approaches to enhance patients' lives.
